|
Market Closed -
Nasdaq
16:00:00 2026-10-21 EDT
|
5-day change | 1st Jan Change | ||
| 5.280 USD | -0.94% |
|
-3.30% | -83.60% |
| Market Cap | 2.57M 2.29M 2.12M 1.92M 3.62M 243M 3.66M 25.46M 9.99M 128M 9.65M 9.45M 407M | P/E 2026 * |
-0.28x | P/E 2027 * | -1.2x |
|---|---|---|---|---|---|
| Enterprise Value | 2.57M 2.29M 2.12M 1.92M 3.62M 243M 3.66M 25.46M 9.99M 128M 9.65M 9.45M 407M | EV / Sales 2026 * |
0.16x | EV / Sales 2027 * | 0.11x |
| Free-Float |
85.98% | Yield 2026 * |
-
| Yield 2027 * | - |
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| NXGL | Delayed | |
CBOE
| NXGL | Real-time |
Last Transcript: NEXGEL, Inc.
| 1 day | -0.94% | ||
| 1 week | -3.30% | ||
| Current month | +52.78% | ||
| 1 month | -0.34% | ||
| 3 months | -39.35% | ||
| 6 months | -64.52% | ||
| Current year | -83.60% |
| 1 week | 4.5 |  | 5.9 |
| 1 month | 3 | | 7.25 |
| Current year | 3 | | 38 |
| 1 year | 3 | | 54.26 |
| 3 years | 3 | | 102 |
| 5 years | 3 | | 102 |
| 10 years | 3 | | 102 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Kieser
CEO | Chief Executive Officer | 59 | 2026-08-20 |
Ian Blackman
DFI | Director of Finance/CFO | 58 | 2026-04-26 |
Gregory J. Robb
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jerome Zeldis
BRD | Director/Board Member | 76 | 2020-03-31 |
Steven Glassman
CHM | Chairman | 61 | - |
| Director/Board Member | 55 | 2025-07-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.94% | -3.30% | -90.50% | -84.19% | 2.57M | |
| -1.01% | +5.13% | +58.93% | +117.36% | 1,133B | |
| -0.61% | +1.52% | +34.34% | +68.48% | 621B | |
| -1.48% | +0.47% | +23.08% | +94.76% | 503B | |
| +0.54% | +5.69% | +39.60% | +64.02% | 379B | |
| +1.07% | +1.70% | +71.06% | +45.98% | 370B | |
| +0.30% | +3.44% | +21.35% | +49.62% | 292B | |
| -0.03% | +2.55% | +1.12% | +20.94% | 262B | |
| -0.14% | +2.87% | +45.56% | +57.22% | 237B | |
| -1.88% | +0.02% | +23.77% | +97.39% | 190B | |
| Average | -0.13% | +2.56% | +22.83% | +53.16% | 398.8B | |
| Weighted average by Cap. | +0.33% | +3.73% | +40.84% | +79.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.79M 14.07M 13.02M 11.79M 22.21M 1.49B 22.47M 156M 61.27M 783M 59.22M 57.99M 2.5B | 24.27M 21.62M 20.02M 18.12M 34.13M 2.29B 34.54M 240M 94.19M 1.2B 91.03M 89.14M 3.84B |
| Net income | -8.33M -7.42M -6.87M -6.22M -11.71M -786M -11.85M -82.37M -32.32M -413M -31.24M -30.59M -1.32B | -2.31M -2.06M -1.91M -1.73M -3.25M -218M -3.29M -22.87M -8.97M -115M -8.67M -8.49M -365M |
| Net Debt | - | - |
Employees
19
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-21 | US$5.280 | -0.94% | 54,212 |
| 26-10-20 | US$5.330 | -8.10% | 28,705 |
| 26-10-19 | US$5.800 | +3.76% | 50,190 |
| 26-10-16 | US$5.590 | +7.92% | 54,785 |
| 26-10-15 | US$5.180 | -5.13% | 165,713 |
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.280
Average target price
-
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NXGL Stock
Select your edition
All financial news and data tailored to specific country editions
